Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Completed · Phase 2
Conditions studied: Myelofibrosis
In brief
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.
Key facts
- Study ID
- NCT00360035
- Run by
- Gemin X
- People needed
- 22
- Starts
- 2006-07-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2013-08-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed myelofibrosis with myeloid metaplasia.
- No limitations on allowable type and amount of prior therapy.
- Patients must have normal organ function.
- Must be willing to submit to blood sampling for planned PK and PD analyzes.
- Must have ability to understand and willingness to sign a written informed consent form.
You may not qualify if…
- No other agents or therapies administered with the intent to treat malignancy.
- Patients with prior exposure to obatoclax.
- Uncontrolled, intercurrent illness.
- Pregnant women and women who are breast feeding.
Where it is running
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- James A. Haley Veterans Hospital — Tampa, Florida, United States
- Emory University — Atlanta, Georgia, United States
- The University of Chicago — Chicago, Illinois, United States
- University of Massachusetts Medical Center — Worcester, Massachusetts, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Princess Margaret Hospital — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.